Altimmune highlighted a broad range of target indications for its “pipeline-in-a-product” candidate pemvidutide in a 13 March R&D Day presentation for investors and analysts that could expand the dual GLP-1/glucagon receptor agonist’s reach far beyond its most advanced indications of metabolic dysfunction-associated steatohepatitis (MASH) and obesity.
Key Takeaways
- Altimmune made a case for its dual GLP-1/glucagon receptor agonist pemvidutide in multiple diseases at an investor day, including MASH and obesity.
- The presentation included hepatic fat reduction data from non-invasive testing that KOLs predicted would be replicated with histology data
The company described the drug as Phase III-ready in obesity, soon to report Phase IIb histology data in MASH and okayed by the US Food and Drug Administration to begin Phase II in two more